EMERGENT BIOSOLUTIONS INC (EBS) Stock Income Statement
NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04B | 1.05B | 1.12B | 1.77B | 1.56B | |||
| Cost Of Goods | 681.30M | 705.40M | 693.10M | 748.10M | 506.70M | |||
| Gross Profit | 362.30M | 343.90M | 424.40M | 1.03B | 1.05B | |||
| Operating Expenses | 443.80M | 545.40M | 587.70M | 642.40M | 568.60M | |||
| Research and Development | 70.70M | 111.40M | 188.30M | 235.20M | 205.50M | |||
| Selling, General, and Administrative Expenses | 308.00M | 368.40M | 339.50M | 348.70M | 303.30M | |||
| Operating Income | -81.50M | -201.50M | -163.30M | 383.10M | 480.10M | |||
| Interest Income/Expense | -71.00M | -87.90M | -37.30M | -34.50M | -31.30M | |||
| Other Income/Expense | 12.50M | 8.90M | -11.70M | -3.70M | 4.70M | |||
| Non Recurring Items | -2.90M | -450.70M | -6.70M | -41.70M | -46.30M | |||
| Income Before Taxes | -142.90M | -731.20M | -219.00M | 303.20M | 407.20M | |||
| Income Tax | 47.70M | 29.30M | -7.40M | 83.70M | 102.10M | |||
| Net Income | -190.60M | -760.50M | -211.60M | 219.50M | 305.10M | |||
| EBITDA | 27.30M | -76.40M | -20.00M | 506.90M | 594.60M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.60 | -14.85 | -4.22 | 4.06 | 5.67 | |||
| Non GAAP EPS | -0.31 | -5.48 | -2.26 | 6.00 | 7.85 | |||
| Statistics | ||||||||
| Gross Profit Margin | 34.72% | 32.77% | 37.98% | 57.82% | 67.42% | |||
| Profit Margin | -18.26% | -72.48% | -18.94% | 12.38% | 19.62% | |||
| Operating Profit Margin | -7.81% | -19.20% | -14.61% | 21.60% | 30.87% | |||
All data in USD